Cancer Science · 2022 · 23 citations · 13 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyGynecologic OncologyEndometrial CancerGynecologic Cancer PharmacotherapyClinical Endpoints CorrelationDoxorubicin-based TherapyEndometrial Cancer ChemotherapyEndometrial Cancer EvaluationLenvatinib TherapyPembrolizumab Therapy
Abstract Study 309/KEYNOTE‐775 is a phase 3 open‐label, randomized trial of lenvatinib plus pembrolizumab versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer with progression after platinum‐based therapy. Primary endpoints of superiority for lenvatinib plus pembrolizumab were met for progression‐free survival (PFS) and overall survival (OS) in all‐comers (ie, regardless of mismatch repair [MMR] status) and patients with MMR proficiency (pMMR). We present results for the Japanese subset. Patients were randomized to oral lenvatinib 20 mg/day plus intravenous pembrolizumab 200 mg every 3 weeks (Q3W; up to 35 cycles of pembrolizumab) or TPC (intravenous doxorubicin 60 mg/m 2 Q3W or paclitaxel 80 mg/m 2 QW [3 weeks on/1 week off]). Primary endpoints were PFS by blinded independent central review per RECIST version 1.1 and OS. One hundred four patients were randomized in Japan (data cutoff, October 26, 2020; median follow‐up, 11.8 [range, 1.1–26.9] months). Hazard ratios (HRs) for PFS with lenvatinib plus pembrolizumab versus TPC were 1.04 (95% CI, 0.63–1.73) in patients with pMMR and 0.81 (0.50–1.31) in all‐comers. Hazard ratios for OS were 0.74 (0.41–1.34) with pMMR and 0.59 (0.33–1.04) for all‐comers. Adverse events were manageable and led to discontinuation of one/both study drugs in 36.5% of patients in the lenvatinib plus pembrolizumab group versus 7.8% in the TPC group. Similar to the global Study 309/KEYNOTE‐775 results, this analysis suggested favorable efficacy and manageable safety with lenvatinib plus pembrolizumab after platinum‐based chemotherapy in Japanese patients with advanced endometrial cancer and supports this combination as a new standard of care in this population.
13
The National Comprehensive Cancer Network (NCCN).
Elizabeth H. Wood · Europe PMC (PubMed Central) · 2004 · 2.9K citations · Full text
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
New England Journal of Medicine · 2022 · 893 citations · Full text
Medicine, Oncology, Pharmacology +8
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker, Matthew H. Taylor, Carol Aghajanian et al. · Journal of Clinical Oncology · 2020 · 522 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE · 2019 · 463 citations · Full text
Life Sciences, Immunology, Oncology +17